Biologics Drug Discovery Market Size, Share & Trends Analysis Distribution By Method (Target Identification/Validation, Hit Generation/Validation, Lead Identification, and Lead Optimization), By Manufacturing Type (In-House Manufacturing and Outsourced Manufacturing), By Type (Monoclonal Antibodies, Recombinant Proteins, and Other Biologics), and Segment Forecasts, 2025-2034

Biologics Drug Discovery Market Size is valued at US$ 22.9 Bn in 2025 and is predicted to reach US$ 54.9 Bn by the year 2034 at an 10.2% CAGR during the forecast period for 2025-2034.

Biologics drug discovery enables the development of highly precise therapies that work in harmony with the body’s natural biological processes. It supports scientists in designing monoclonal antibodies, protein-based drugs, and cell-derived therapies for conditions that often resist traditional small-molecule treatments. Because biologics offer targeted action with reduced side effects, they are widely used in oncology, autoimmune disorders, and rare diseases. By tailoring treatments to specific biomarkers, biologics significantly improve therapeutic effectiveness. Overall, this field expands the options available for complex diseases and drives innovation in next-generation therapeutics. As healthcare systems shift toward more accurate and durable treatments, the global biologics drug discovery market continues to grow.

The rise in cancer, autoimmune diseases, and chronic illnesses is another element propelling the Biologics Drug Discovery market. The market is expanding because of growing need for targeted medicines that are more effective than conventional medications at treating complicated and chronic disorders. The WHO estimates that there were around 9.7 million deaths resulted from cancer globally. About 1 in 5 people will develop cancer during their lifetime; about 1 in 9 men and 1 in 12 women will die from it.

However, biologics development is an expensive and time-consuming process that frequently calls for intricate production procedures and stringent quality standards are some of the obstacles impeding the growth of the Biologics Drug Discovery sector. Over the course of the forecast period, opportunities for the Biologics Drug Discovery market will be created by integration of artificial intelligence (AI) into biologics drug discovery. 

Competitive Landscape

Which are the Leading Players in Biologics Drug Discovery Market?

·       Alloy Therapeutics, Inc.

·       Charles River Laboratories International, Inc.

·       Regeneron Pharmaceuticals, Inc.

·       WuXi Biologics (Cayman) Inc.

·       AbbVie Inc.

·       Amgen, Inc.

·       Astellas Pharma Inc.

·       AstraZeneca Plc

·       Bristol-Myers Squibb

·       Novo Nordisk A/S

·       Novartis AG

·       Evotec SE

·       Eli Lilly and Company

·       GenScript Biotech Corporation

·       Gilead Sciences, Inc.

·       Merck KGaA

·       Others

Market Segmentation:

The biologics drug discovery market is segmented by method, by manufacturing type, and type. By method, the market is segmented into target identification/validation, hit generation/validation, lead identification, and lead optimization. By manufacturing type, the market is segmented into in-house manufacturing and outsourced manufacturing. By type, the market is segmented into monoclonal antibodies, recombinant proteins, and other biologics.

By Method, the Target Identification/Validation Segment is Expected to Drive the Biologics Drug Discovery Market

The target identification/validation segment led the biologics drug discovery market in 2024. In the early phases of biologics development, this section is crucial since the success of therapeutic initiatives depends on the identification of possible drug candidates, such as antibody therapies. Phage display screening and hybridoma screening are two of the most used techniques in hit creation and validation; both are essential for producing and verifying high-affinity antibodies. While hybridoma screening remains a key component of the manufacturing of monoclonal antibodies, phage display enables the quick screening of huge antibody libraries to select specific candidates.

Outsourced Manufacturing Segment is Growing at the Highest Rate in the Biologics Drug Discovery Market

Outsourced Manufacturing segment represents the largest and fastest-growing manufacturing type in biologics drug discovery, driven by its ability to reduce operating costs, enhance scalability, and provide access to specialized expertise. By partnering with contract manufacturing organizations (CMOs), companies can leverage advanced capabilities such as high-throughput screening, large-scale biologics production, and state-of-the-art bioprocessing without heavy capital investment. This model is especially vital for small and mid-size biotechs, which rely on external partners to support the discovery, development, and manufacturing of monoclonal antibodies, recombinant proteins, and cell and gene therapies. As biologics pipelines expand, outsourcing continues to accelerate innovation and operational efficiency across the industry.

Why North America Led the Biologics Drug Discovery Market?

North America dominated the biologics drug discovery market in 2024. The United States is at the forefront of this expansion. This is due to the region's strong combination of cutting-edge research facilities, well-funded biotechnology businesses, and consistent government backing for novel therapeutics, are attributed to this. Demand is maintained by a high prevalence of complicated and chronic illnesses, and development is facilitated by well-established regulatory frameworks. Major pharmaceutical companies, a wealth of venture funding, and access to highly qualified scientific staff further solidify North America's position as the industry's premier hub.

Rapidly growing biotech capabilities becoming more and more common in the Asia-Pacific area, the biologics drug discovery market is expanding at the strongest and fastest rate in this region. Additionally, the need for biologic medicines is increasing due to rising rates of autoimmune diseases, cancer, and chronic illnesses. To encourage collaborations, governments are constructing research parks, enhancing regulatory processes, and providing incentives. The region is expanding rapidly and gaining international momentum thanks to lower development costs, a sizable patient pool, and expanding industry-academia partnerships.

Biologics Drug Discovery Market Report Scope